Jerel Allen

@jadapsmith @RedTableTalk @GwynethPaltrow If you want August back just say that!!

Only because I got time today. Stop making up headlines. Watch the @RedTableTalk I did with @GwynethPaltrow for yourselves. Will and I have NEVER had an issue in the bedroom. Thank you❣️fb.me/RTTGwynethPalt…

#Ampion & #COVID19🦠: Ampion interrupts the hyperactive immune response associated with COVID-19 and may improve the clinical outcome for patients suffering from complications.

@HectorGoleador @AmpioPharmaInc Drop a P.R

@AmpioPharmaInc PR. PR. PR. PR

DID YOU KNOW? 🧐 #COVID19 patients who received #Ampion required less oxygen than standard of care alone, and 86% of Ampion patients were stable or had improvement compared to 75% of SOC patients.

ADVOCATE FOR AWARENESS: Research and development of Ampion for use in Kawasaki Disease is being explored based on preclinical pharmacology studies showing #Ampion to reduce inflammatory cytokines while promoting the production of prostaglandins. #biotech #platformdrug $AMPE

Therapeutics will continue to be necessary to treat patients impacted by #COVID19. #ICYMI: Data suggests people with COVID19 can continue to suffer from symptoms for 9+ months. These long-hauler symptoms are called Post-Acute Sequelae of COVID-19 or #PASC. $AMPE #platformdrug

READ 📰: Chairman and CEO Michael Macaluso discusses Ampion’s strength as a platform therapeutic with broad applicability. More in @PharmaOutlook’s 2021 Immunotherapy Solution Providers Edition: #page=20" target="_blank" rel="nofollow noopener">pharmatechoutlook.com/magazines/July… #biotech #platformdrug $AMPE

What makes Ampion different? Inflammation is an important, even essential part of the immune response, so if one pathway is blocked, the body often finds ways around the block and the #inflammation continues. #platformdrug #biotech $AMPE

$AMPE #biotech #platformdrug

3 -10 million people are suffering from #longhauler effects of #COVID19. Ampio received IRB approval to begin enrollment in the AP-018 Phase I study using inhaled Ampion to treat patients exhibiting prolonged respiratory COVID-19 symptoms. $AMPE More: bit.ly/33uSm7Q

What makes Ampion different? ☑️Ampion is safe ☑️Ampion is a platform drug ☑️Ampion works on multiple pathways of inflammation ☑️Ampion offers flexibility in multiple delivery methods ☑️Ampion promotes healing ☑️Ampion regulates inflammation

#COVID19 patients who received Ampio required less hospitalization time. The average hospital length of stay was 4 days less for the Ampion group compared to the patients receiving SOC.

See the latest updates from our Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in #COVID19 🦠 patients as well as details on our Phase I clinical trial treating #LongHauler #COVID19 symptoms: bit.ly/3trRsUU

Read on for Ampio’s research into indications in kidney and pediatric diseases: bit.ly/3trRsUU

@MrZackMorris Bro look into ampio.

I’ll find fresh plays on Monday. Too much bs going on with the brokers.

@MrZackMorris if you have time please look into ampio pharmacy. It’s a game changer and covid19 play and phase 3 oak.

#COVID19 is mutating, so an effective vaccine today may not be effective tomorrow. 😷 Like the common cold and flu, COVID could require constant vaccine development. In the meantime, people need therapies like #Ampion to relieve damaging inflammation caused by these viruses.

$AMPE AMPIO REPORTS POSITIVE RESULTS FOR AMPION TREATMENT IN COVID-19 PATIENTS #COVID19 #COVID #COVID19research #covid19news #covidrecovery ampiopharma.com/news/ampio-rep…

@ShannonSharpe you better chill on @RealSkipBayless today 🤣🤣🤣